{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:19:20Z","timestamp":1788304760761,"version":"build-2803163510"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01987-3","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T09:09:14Z","timestamp":1765184954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-omics profiling and AI-driven clinically deployable risk models in MGUS and smoldering myeloma"],"prefix":"10.1007","volume":"26","author":[{"given":"Yanyun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-2595","authenticated-orcid":false,"given":"Sina","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"21","key":"1987_CR1","first-page":"5573","volume":"117","author":"N Korde","year":"2011","unstructured":"Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood J Am Soc Hematol. 2011;117(21):5573\u201381.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"1987_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","volume":"14","author":"CT Wallington-Beddoe","year":"2021","unstructured":"Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol. 2021;14(1):151.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1987_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/bfgp\/elac017","volume":"22","author":"MA Dar","year":"2023","unstructured":"Dar MA, et al. Multiomics technologies: role in disease biomarker discoveries and therapeutics. Brief Funct Genomics. 2023;22(2):76\u201396.","journal-title":"Brief Funct Genomics"},{"issue":"3","key":"1987_CR4","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1002\/qub2.70002","volume":"13","author":"A Yetgin","year":"2025","unstructured":"Yetgin A. Revolutionizing multi-omics analysis with artificial intelligence and data processing. Quant Biology. 2025;13(3):e70002.","journal-title":"Quant Biology"},{"issue":"3","key":"1987_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.55248\/gengpi.5.0224.0421","volume":"1","author":"A Kumar","year":"2024","unstructured":"Kumar A, Metta D. AI-driven precision oncology: predictive biomarker discovery and personalized treatment optimization using genomic data. Int J Adv Res Publ Rev. 2024;1(3):21\u201338.","journal-title":"Int J Adv Res Publ Rev"},{"issue":"7","key":"1987_CR6","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona E, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586\u201392.","journal-title":"Blood"},{"issue":"3","key":"1987_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812\u20137.","journal-title":"Blood"},{"issue":"3","key":"1987_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.33696\/immunology.6.199","volume":"6","author":"DD Lee","year":"2024","unstructured":"Lee DD, Davies FE, Morgan GJ. Evolution of the classification and management of smoldering multiple myeloma. J Cell Immunol. 2024;6(3):125\u201339.","journal-title":"J Cell Immunol"},{"key":"1987_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fonc.2018.00665","volume":"8","author":"KK Jovanovi\u0107","year":"2019","unstructured":"Jovanovi\u0107 KK, et al. Deregulation and targeting of TP53 pathway in multiple myeloma. Front Oncol. 2019;8:665.","journal-title":"Front Oncol"},{"key":"1987_CR10","doi-asserted-by":"crossref","unstructured":"Avigan ZM, Mitsiades CS, Lagan\u00e0 A. The role of 1q abnormalities in multiple myeloma: genomic insights, clinical implications, and therapeutic challenges. Seminars in hematology. Elsevier; 2025.","DOI":"10.1053\/j.seminhematol.2024.10.001"},{"issue":"9","key":"1987_CR11","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324.","journal-title":"Am J Hematol"},{"issue":"1","key":"1987_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/hematology.2021000304","volume":"2021","author":"A Visram","year":"2021","unstructured":"Visram A, Cook J, Warsame R. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. Hematology. 2021;2021(1):673\u201381.","journal-title":"Hematology"},{"issue":"3","key":"1987_CR13","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1002\/hem3.61","volume":"8","author":"G Mellgard","year":"2024","unstructured":"Mellgard G, et al. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere. 2024;8(3):e61.","journal-title":"HemaSphere"},{"issue":"1","key":"1987_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","volume":"25","author":"EJ Topol","year":"2019","unstructured":"Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44\u201356.","journal-title":"Nat Med"},{"key":"1987_CR15","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Neoplast Dis Blood, 2012: pp. 751\u201385.","DOI":"10.1007\/978-1-4614-3764-2_38"},{"key":"1987_CR16","unstructured":"Corsale AM. Prediction of progression to symptomatic multiple myeloma in patients with high-risk plasma cell dyscrasias. 2025."},{"issue":"1","key":"1987_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","volume":"482","author":"F Fend","year":"2023","unstructured":"Fend F, Dogan A, Cook JR. Plasma cell neoplasms and related entities\u2014evolution in diagnosis and classification. Virchows Arch. 2023;482(1):163\u201377.","journal-title":"Virchows Arch"},{"key":"1987_CR18","unstructured":"Moritz DY. Multiple myeloma and other plasma cell diseases. University of Zagreb. School of Medicine. Department of Internal Medicine; 2019."},{"key":"1987_CR19","unstructured":"Halvarsson B-M. Genetic predisposition to sporadic and Familial multiple myeloma. Lund University; 2022."},{"issue":"6","key":"1987_CR20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3324\/haematol.2022.281802","volume":"108","author":"LY Chen","year":"2022","unstructured":"Chen LY, et al. Monoclonal gammopathy of increasing significance: time to screen? Haematologica. 2022;108(6):1476.","journal-title":"Haematologica"},{"key":"1987_CR21","doi-asserted-by":"crossref","unstructured":"Li C et al. Global patterns and trends in multiple myeloma incidence: Age, period and birth cohort analysis. 2022.","DOI":"10.21203\/rs.3.rs-1977463\/v1"},{"issue":"23","key":"1987_CR22","first-page":"2599","volume":"128","author":"MV Dhodapkar","year":"2016","unstructured":"Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood J Am Soc Hematol. 2016;128(23):2599\u2013606.","journal-title":"Blood J Am Soc Hematol"},{"issue":"10","key":"1987_CR23","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","volume":"78","author":"N van Nieuwenhuijzen","year":"2018","unstructured":"van Nieuwenhuijzen N, et al. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78(10):2449\u201356.","journal-title":"Cancer Res"},{"issue":"12","key":"1987_CR24","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1038\/s41375-020-01051-x","volume":"34","author":"M Ho","year":"2020","unstructured":"Ho M, et al. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia. 2020;34(12):3111\u201325.","journal-title":"Leukemia"},{"key":"1987_CR25","unstructured":"Dalla Palma AB. Risk factors of short-term progression in patients with monoclonal gammopathies. 2021."},{"key":"1987_CR26","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstr\u00f6m macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. in Mayo Clinic Proceedings. 2006. Elsevier.","DOI":"10.4065\/81.5.693"},{"issue":"12","key":"1987_CR27","doi-asserted-by":"publisher","first-page":"e70031","DOI":"10.1002\/hem3.70031","volume":"8","author":"V Gonz\u00e1lez-Calle","year":"2024","unstructured":"Gonz\u00e1lez-Calle V, et al. High\u2010risk cytogenetic abnormalities in multiple myeloma: PETHEMA\u2010GEM experience. HemaSphere. 2024;8(12):e70031.","journal-title":"HemaSphere"},{"issue":"3","key":"1987_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"1987_CR29","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","volume":"54","author":"BM Cherry","year":"2013","unstructured":"Cherry BM, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma. 2013;54(10):2215\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"1987_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, et al. International myeloma working group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1987_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59.","journal-title":"Blood Cancer J"},{"key":"1987_CR32","doi-asserted-by":"crossref","unstructured":"Zanwar S, Rajkumar SV. Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders: MULTIPLE MYELOMA, GAMMOPATHIES. Leukemia, 2025: pp. 1\u20138.","DOI":"10.1038\/s41375-025-02654-y"},{"key":"1987_CR33","unstructured":"K\u00f6se MC. Understanding Disease Progression and Target Identification for Multiple Myeloma. 2023, Universite de Liege (Belgium)."},{"issue":"1","key":"1987_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10238-025-01783-z","volume":"25","author":"M Abdar Esfahani","year":"2025","unstructured":"Abdar Esfahani M, et al. The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations. Clin Experimental Med. 2025;25(1):230.","journal-title":"Clin Experimental Med"},{"key":"1987_CR35","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S350238","author":"M Ram","year":"2024","unstructured":"Ram M, et al. The genetic and molecular drivers of multiple myeloma: current insights, clinical implications, and the path forward. Pharmacogenomics Person Med. 2024. https:\/\/doi.org\/10.2147\/PGPM.S350238.","journal-title":"Pharmacogenomics Person Med"},{"key":"1987_CR36","unstructured":"Christina YY. Computational network mining in High-Risk patients with multiple myeloma. The Ohio State University; 2020."},{"issue":"1","key":"1987_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10238-025-01902-w","volume":"25","author":"M Pirouzbakht","year":"2025","unstructured":"Pirouzbakht M, Hamzeh S, Soleimani H, Samarkhazan. Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers. Clin Exp Med. 2025;25(1):355.","journal-title":"Clin Exp Med"},{"issue":"7","key":"1987_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12032-025-02807-0","volume":"42","author":"H Sutanto","year":"2025","unstructured":"Sutanto H, et al. Genetic, epigenetic, and molecular determinants of multiple myeloma and precursor plasma cell disorders: a pathophysiological overview. Med Oncol. 2025;42(7):234.","journal-title":"Med Oncol"},{"issue":"1","key":"1987_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00236-z","volume":"10","author":"L Xu","year":"2021","unstructured":"Xu L, Su Y. Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications. Exp Hematol Oncol. 2021;10(1):43.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1987_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5603\/AHP.2021.0004","volume":"52","author":"S Goldman-Mazur","year":"2021","unstructured":"Goldman-Mazur S, Vesole DH, Jurczyszyn A. Clinical implications of cytogenetic and molecular aberrations in multiple myeloma. Acta Haematol Pol. 2021;52(1):18\u201328.","journal-title":"Acta Haematol Pol"},{"issue":"4","key":"1987_CR41","first-page":"1919","volume":"12","author":"A Farswan","year":"2022","unstructured":"Farswan A, et al. Characterizing the mutational landscape of MM and its precursor MGUS. Am J Cancer Res. 2022;12(4):1919\u2013p.","journal-title":"Am J Cancer Res"},{"key":"1987_CR42","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3389\/fgene.2019.00424","volume":"10","author":"S Janz","year":"2019","unstructured":"Janz S, et al. Germline risk contribution to genomic instability in multiple myeloma. Front Genet. 2019;10:424.","journal-title":"Front Genet"},{"issue":"23","key":"1987_CR43","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.3390\/cancers13235949","volume":"13","author":"AY Aksenova","year":"2021","unstructured":"Aksenova AY, et al. Genome instability in multiple myeloma: facts and factors. Cancers. 2021;13(23):5949.","journal-title":"Cancers"},{"issue":"2","key":"1987_CR44","first-page":"553","volume":"117","author":"BA Walker","year":"2011","unstructured":"Walker BA, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. J Am Soc Hematol. 2011;117(2):553\u201362.","journal-title":"J Am Soc Hematol"},{"issue":"15","key":"1987_CR45","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1038\/sj.onc.1208447","volume":"24","author":"M Mattioli","year":"2005","unstructured":"Mattioli M, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 2005;24(15):2461\u201373.","journal-title":"Oncogene"},{"key":"1987_CR46","doi-asserted-by":"publisher","first-page":"104916","DOI":"10.1016\/j.critrevonc.2025.104916","volume":"215","author":"M Huang","year":"2025","unstructured":"Huang M, et al. Epigenetic mechanisms and next-gen editing platforms in hematology: from molecular basis to therapeutic frontiers. Crit Rev Oncol Hematol. 2025;215:104916.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"1987_CR47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s13402-018-0395-3","volume":"41","author":"K Bhawe","year":"2018","unstructured":"Bhawe K, Roy D. Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression. Cell Oncol. 2018;41(5):465\u201384.","journal-title":"Cell Oncol"},{"issue":"2","key":"1987_CR48","doi-asserted-by":"publisher","first-page":"640","DOI":"10.14336\/AD.2023.0520","volume":"15","author":"KI Chan","year":"2024","unstructured":"Chan KI, et al. MYC oncogene: a druggable target for treating cancers with natural products. Aging Disease. 2024;15(2):640.","journal-title":"Aging Disease"},{"key":"1987_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117225","volume":"178","author":"F Li","year":"2024","unstructured":"Li F, et al. A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1). Biomed Pharmacother. 2024;178:117225.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1987_CR50","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/cancers16030498","volume":"16","author":"L Gong","year":"2024","unstructured":"Gong L, Qiu L, Hao M. Novel insights into the initiation, evolution, and progression of multiple myeloma by multi-omics investigation. Cancers. 2024;16(3):498.","journal-title":"Cancers"},{"key":"1987_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17298","author":"J Aljabban","year":"2023","unstructured":"Aljabban J, et al. Characterization of monoclonal gammopathy of undetermined significance progression to multiple myeloma through meta-analysis of GEO data. Heliyon. 2023. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17298.","journal-title":"Heliyon"},{"issue":"2","key":"1987_CR52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1385\/MB:34:2:125","volume":"34","author":"PM Nissom","year":"2006","unstructured":"Nissom PM, et al. Transcriptome and proteome profiling to Understanding the biology of high productivity CHO cells. Mol Biotechnol. 2006;34(2):125\u201340.","journal-title":"Mol Biotechnol"},{"issue":"9","key":"1987_CR53","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.3390\/ijms22094462","volume":"22","author":"N Giannakoulas","year":"2021","unstructured":"Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. Int J Mol Sci. 2021;22(9):4462.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"1987_CR54","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","volume":"6","author":"C Schinke","year":"2022","unstructured":"Schinke C, et al. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022;6(22):5873\u201383.","journal-title":"Blood Adv"},{"issue":"13","key":"1987_CR55","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.3390\/cancers13133213","volume":"13","author":"C Botta","year":"2021","unstructured":"Botta C, et al. Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities. Cancers. 2021;13(13):3213.","journal-title":"Cancers"},{"issue":"9","key":"1987_CR56","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/cancers14092278","volume":"14","author":"M Chahin","year":"2022","unstructured":"Chahin M, et al. Clinical considerations for immunoparesis in multiple myeloma. Cancers. 2022;14(9):2278.","journal-title":"Cancers"},{"issue":"11","key":"1987_CR57","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.3390\/cancers13112542","volume":"13","author":"P Maiso","year":"2021","unstructured":"Maiso P, et al. Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression. Cancers. 2021;13(11):2542.","journal-title":"Cancers"},{"issue":"13","key":"1987_CR58","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.3390\/cancers14133271","volume":"14","author":"AG Solimando","year":"2022","unstructured":"Solimando AG, et al. The route of the malignant plasma cell in its survival niche: exploring multiple myelomas. Cancers. 2022;14(13):3271.","journal-title":"Cancers"},{"key":"1987_CR59","doi-asserted-by":"crossref","unstructured":"Li L et al. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis. Front Immunol, 2024. Volume 15\u20132024.","DOI":"10.3389\/fimmu.2024.1381212"},{"key":"1987_CR60","unstructured":"Trudu M. INTEGRATED ROLE OF MITOCHONDRIA IN MULTIPLE MYELOMA. 2024."},{"key":"1987_CR61","doi-asserted-by":"publisher","first-page":"1000106","DOI":"10.3389\/fonc.2022.1000106","volume":"12","author":"R Nair","year":"2022","unstructured":"Nair R, Gupta P, Shanmugam M. Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy. Front Oncol. 2022;12:1000106.","journal-title":"Front Oncol"},{"issue":"9","key":"1987_CR62","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.3390\/ijms25094644","volume":"25","author":"C Jim\u00e9nez","year":"2024","unstructured":"Jim\u00e9nez C, et al. Characterization of human B cell hematological malignancies using protein-based approaches. Int J Mol Sci. 2024;25(9):4644.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1987_CR63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11(4):83.","journal-title":"Blood Cancer J"},{"key":"1987_CR64","first-page":"573","volume":"17","author":"M Ram","year":"2024","unstructured":"Ram M, et al. The genetic and molecular drivers of multiple myeloma: current Insights, clinical Implications, and the path forward. Pharmgenomics Pers Med. 2024;17:573\u2013609.","journal-title":"Pharmgenomics Pers Med"},{"key":"1987_CR65","doi-asserted-by":"crossref","unstructured":"Maura F et al. Genomics define malignant transformation in myeloma precursor conditions. J Clin Oncol. 2025; Jco2501733.","DOI":"10.1016\/S2152-2650(25)03448-2"},{"key":"1987_CR66","unstructured":"Alberge J-B et al. Genomic landscape of multiple myeloma and its precursor conditions. Nat Genet. 2025; 1\u201311."},{"issue":"4","key":"1987_CR67","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s12033-024-01133-6","volume":"67","author":"A Mukherjee","year":"2025","unstructured":"Mukherjee A, et al. From data to cure: a comprehensive exploration of multi-omics data analysis for targeted therapies. Mol Biotechnol. 2025;67(4):1269\u201389.","journal-title":"Mol Biotechnol"},{"issue":"2","key":"1987_CR68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41416-024-02706-7","volume":"131","author":"NA Valous","year":"2024","unstructured":"Valous NA, et al. Graph machine learning for integrated multi-omics analysis. Br J Cancer. 2024;131(2):205\u201311.","journal-title":"Br J Cancer"},{"issue":"6","key":"1987_CR69","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s42256-021-00325-y","volume":"3","author":"R Schulte-Sasse","year":"2021","unstructured":"Schulte-Sasse R, et al. Integration of multiomics data with graph convolutional networks to identify new cancer genes and their associated molecular mechanisms. Nat Mach Intell. 2021;3(6):513\u201326.","journal-title":"Nat Mach Intell"},{"issue":"9","key":"1987_CR70","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1109\/JBHI.2023.3284794","volume":"27","author":"S Xiao","year":"2023","unstructured":"Xiao S, et al. Graph neural networks with multiple prior knowledge for multi-omics data analysis. IEEE J Biomedical Health Inf. 2023;27(9):4591\u2013600.","journal-title":"IEEE J Biomedical Health Inf"},{"key":"1987_CR71","doi-asserted-by":"publisher","first-page":"967205","DOI":"10.3389\/fmolb.2022.967205","volume":"9","author":"FE Agamah","year":"2022","unstructured":"Agamah FE, et al. Computational approaches for network-based integrative multi-omics analysis. Front Mol Biosci. 2022;9:967205.","journal-title":"Front Mol Biosci"},{"key":"1987_CR72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1109\/RBME.2021.3122522","volume":"16","author":"R Li","year":"2021","unstructured":"Li R, et al. Graph signal processing, graph neural network and graph learning on biological data: a systematic review. IEEE Rev Biomed Eng. 2021;16:109\u201335.","journal-title":"IEEE Rev Biomed Eng"},{"key":"1987_CR73","doi-asserted-by":"publisher","first-page":"107303","DOI":"10.1016\/j.compbiomed.2023.107303","volume":"164","author":"D Ouyang","year":"2023","unstructured":"Ouyang D, et al. Integration of multi-omics data using adaptive graph learning and attention mechanism for patient classification and biomarker identification. Comput Biol Med. 2023;164:107303.","journal-title":"Comput Biol Med"},{"key":"1987_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac405","author":"B He","year":"2022","unstructured":"He B, et al. DGHNE: network enhancement-based method in identifying disease-causing genes through a heterogeneous biomedical network. Brief Bioinform. 2022. https:\/\/doi.org\/10.1093\/bib\/bbac405.","journal-title":"Brief Bioinform"},{"issue":"12","key":"1987_CR75","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.3390\/cancers13123047","volume":"13","author":"X Zhang","year":"2021","unstructured":"Zhang X, et al. OmiEmbed: a unified multi-task deep learning framework for multi-omics data. Cancers. 2021;13(12):3047.","journal-title":"Cancers"},{"issue":"6","key":"1987_CR76","doi-asserted-by":"publisher","first-page":"bbab315","DOI":"10.1093\/bib\/bbab315","volume":"22","author":"E Withnell","year":"2021","unstructured":"Withnell E, et al. XOmiVAE: an interpretable deep learning model for cancer classification using high-dimensional omics data. Brief Bioinform. 2021;22(6):bbab315.","journal-title":"Brief Bioinform"},{"key":"1987_CR77","doi-asserted-by":"publisher","first-page":"112774","DOI":"10.1016\/j.knosys.2024.112774","volume":"309","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, et al. Dual alignment feature embedding network for multi-omics data clustering. Knowl Based Syst. 2025;309:112774.","journal-title":"Knowl Based Syst"},{"issue":"2","key":"1987_CR78","doi-asserted-by":"publisher","first-page":"bbab600","DOI":"10.1093\/bib\/bbab600","volume":"23","author":"C Zhang","year":"2022","unstructured":"Zhang C, et al. Deep latent space fusion for adaptive representation of heterogeneous multi-omics data. Brief Bioinform. 2022;23(2):bbab600.","journal-title":"Brief Bioinform"},{"issue":"2","key":"1987_CR79","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/cancers17020332","volume":"17","author":"N Karathanasis","year":"2025","unstructured":"Karathanasis N, Spyrou GM. Predicting the progression from asymptomatic to symptomatic multiple myeloma and stage classification using gene expression data. Cancers. 2025;17(2):332.","journal-title":"Cancers"},{"issue":"1","key":"1987_CR80","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-023-01472-y","volume":"16","author":"F Sun","year":"2023","unstructured":"Sun F, et al. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023;16(1):70.","journal-title":"J Hematol Oncol"},{"key":"1987_CR81","doi-asserted-by":"publisher","first-page":"p6782046","DOI":"10.1155\/2020\/6782046","volume":"2020","author":"B He","year":"2020","unstructured":"He B, et al. Gene coexpression network and module analysis across 52 human tissues. Biomed Res Int. 2020;2020:p6782046.","journal-title":"Biomed Res Int"},{"issue":"15","key":"1987_CR82","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.3390\/electronics14153014","volume":"14","author":"A Santamar\u00eda","year":"2025","unstructured":"Santamar\u00eda A, et al. Machine learning-based predictive model for risk stratification of multiple myeloma from monoclonal gammopathy of undetermined significance. Electronics. 2025;14(15):3014.","journal-title":"Electronics"},{"issue":"1","key":"1987_CR83","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41408-023-00798-7","volume":"13","author":"AJ Ryu","year":"2023","unstructured":"Ryu AJ, et al. Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance. Blood Cancer J. 2023;13(1):28.","journal-title":"Blood Cancer J"},{"key":"1987_CR84","doi-asserted-by":"publisher","first-page":"107117","DOI":"10.1016\/j.compbiomed.2023.107117","volume":"163","author":"J Zhu","year":"2023","unstructured":"Zhu J, et al. Geometric graph neural networks on multi-omics data to predict cancer survival outcomes. Comput Biol Med. 2023;163:107117.","journal-title":"Comput Biol Med"},{"key":"1987_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymeth.2023.02.011","volume":"213","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, et al. Local augmented graph neural network for multi-omics cancer prognosis prediction and analysis. Methods. 2023;213:1\u20139.","journal-title":"Methods"},{"issue":"8","key":"1987_CR86","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s42256-024-00868-w","volume":"6","author":"R Jiang","year":"2024","unstructured":"Jiang R, et al. A transformer-based weakly supervised computational pathology method for clinical-grade diagnosis and molecular marker discovery of gliomas. Nat Mach Intell. 2024;6(8):876\u201391.","journal-title":"Nat Mach Intell"},{"key":"1987_CR87","doi-asserted-by":"publisher","first-page":"pbaab026","DOI":"10.1093\/database\/baab026","volume":"2021","author":"S Tim\u00f3n-Reina","year":"2021","unstructured":"Tim\u00f3n-Reina S, Rinc\u00f3n M, Mart\u00ednez-Tom\u00e1s R. An overview of graph databases and their applications in the biomedical domain. Database. 2021;2021:pbaab026.","journal-title":"Database"},{"key":"1987_CR88","unstructured":"Shah V. Genetics of high risk myeloma. 2021."},{"key":"1987_CR89","doi-asserted-by":"crossref","unstructured":"Claussen CM et al. Gene expression profiling predicts clinical outcomes in newly diagnosed multiple myeloma patients in a standard of care setting. 2016, American Society of Hematology Washington, DC.","DOI":"10.1182\/blood.V128.22.5628.5628"},{"issue":"3","key":"1987_CR90","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","volume":"10","author":"A Cowan","year":"2023","unstructured":"Cowan A, et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023;10(3):e203\u201312.","journal-title":"Lancet Haematol"},{"issue":"4","key":"1987_CR91","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109(4):1692\u2013700.","journal-title":"Blood"},{"issue":"12","key":"1987_CR92","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3109\/10428194.2010.525725","volume":"51","author":"S Mailankody","year":"2010","unstructured":"Mailankody S, et al. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leuk Lymphoma. 2010;51(12):2159\u201370.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1987_CR93","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11899-020-00569-2","volume":"15","author":"S Seth","year":"2020","unstructured":"Seth S, et al. Monoclonal gammopathy of undetermined significance: current concepts and future prospects. Curr Hematol Malig Rep. 2020;15(2):45\u201355.","journal-title":"Curr Hematol Malig Rep"},{"issue":"25","key":"1987_CR94","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1200\/JCO.2008.19.1916","volume":"27","author":"A Anguiano","year":"2009","unstructured":"Anguiano A, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and May guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol. 2009;27(25):4197\u2013203.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1987_CR95","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1182\/blood.V128.22.3275.3275","volume":"128","author":"R van Laar","year":"2016","unstructured":"van Laar R, et al. The 70-Gene MyPRSR prognostic risk score signature predicts increased risk of progression from MGUS to multiple myeloma requring treatment. Blood. 2016;128(22):3275.","journal-title":"Blood"},{"issue":"9","key":"1987_CR96","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/ijc.35057","volume":"155","author":"JR Li","year":"2024","unstructured":"Li JR, Wang C, Cheng C. Identifying high-risk multiple myeloma patients: a novel approach using a clonal gene signature. Int J Cancer. 2024;155(9):1684\u201395.","journal-title":"Int J Cancer"},{"key":"1987_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cells14171385","author":"SQ Alhamrani","year":"2025","unstructured":"Alhamrani SQ, et al. Machine learning for multi-omics characterization of blood cancers: a systematic review. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14171385.","journal-title":"Cells"},{"key":"1987_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaf405","author":"Y Dou","year":"2025","unstructured":"Dou Y, Mirzaei G. MO-GCAN: multi-omics integration based on graph convolutional and attention networks. Bioinformatics. 2025. https:\/\/doi.org\/10.1093\/bioinformatics\/btaf405.","journal-title":"Bioinformatics"},{"key":"1987_CR99","unstructured":"Spandana C, Kumar R, Gautam A. Cancer Detect Hum Blood Samples Using Mach Learn Techniques."},{"issue":"10","key":"1987_CR100","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.clml.2019.09.089","volume":"19","author":"M Bauer","year":"2019","unstructured":"Bauer M, et al. A detailed exploration of using RNA-Seq data in established multiple myeloma gene expression profile microarray based risk scores. Clin Lymphoma Myeloma Leuk. 2019;19(10):e57\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1987_CR101","doi-asserted-by":"crossref","unstructured":"Alharbi F et al. Comparative analysis of multi-omics integration using advanced graph neural networks for cancer classification. arXiv preprint arXiv:2410.05325, 2024.","DOI":"10.1109\/ACCESS.2025.3540769"},{"issue":"1","key":"1987_CR102","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/bjh.17837","volume":"196","author":"YH Wang","year":"2022","unstructured":"Wang YH, et al. Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome. Br J Haematol. 2022;196(1):156\u201368.","journal-title":"Br J Haematol"},{"key":"1987_CR103","doi-asserted-by":"publisher","first-page":"932852","DOI":"10.3389\/fonc.2022.932852","volume":"12","author":"V Ferla","year":"2022","unstructured":"Ferla V, et al. Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy. Front Oncol. 2022;12:932852.","journal-title":"Front Oncol"},{"key":"1987_CR104","doi-asserted-by":"publisher","DOI":"10.32604\/cmc.2025.065571","author":"AM Al-Zoghby","year":"2025","unstructured":"Al-Zoghby AM, et al. A comprehensive review of multimodal deep learning for enhanced medical diagnostics. Computers, Materials & Continua. 2025. https:\/\/doi.org\/10.32604\/cmc.2025.065571.","journal-title":"Computers, Materials & Continua"},{"key":"1987_CR105","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3389\/fbioe.2020.00817","volume":"8","author":"B He","year":"2020","unstructured":"He B, et al. Assessing the impact of data preprocessing on analyzing next generation sequencing data. Front Bioeng Biotechnol. 2020;8:817.","journal-title":"Front Bioeng Biotechnol"},{"issue":"9","key":"1987_CR106","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","volume":"5","author":"O Landgren","year":"2019","unstructured":"Landgren O, et al. Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma. JAMA Oncol. 2019;5(9):1293\u2013301.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1987_CR107","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1078-0432.CCR-12-2922","volume":"19","author":"A Agarwal","year":"2013","unstructured":"Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res. 2013;19(5):985\u201394.","journal-title":"Clin Cancer Res"},{"key":"1987_CR108","doi-asserted-by":"publisher","first-page":"1081885","DOI":"10.3389\/fonc.2023.1081885","volume":"13","author":"L Licata","year":"2023","unstructured":"Licata L, et al. Multigene signatures for early breast cancer in clinical practice: a report of the Lombardy genomic assays for breast cancer working group. Front Oncol. 2023;13:1081885.","journal-title":"Front Oncol"},{"issue":"5","key":"1987_CR109","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1586\/erm.09.32","volume":"9","author":"EA Slodkowska","year":"2009","unstructured":"Slodkowska EA, Ross JS. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009;9(5):417\u201322.","journal-title":"Expert Rev Mol Diagn"},{"issue":"09","key":"1987_CR110","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/s-0033-1350831","volume":"73","author":"P Sinn","year":"2013","unstructured":"Sinn P, et al. Multigene assays for classification, prognosis, and prediction in breast cancer: a critical review on the background and clinical utility. Geburtshilfe Frauenheilkd. 2013;73(09):932\u201340.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"1987_CR111","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1755-8794-7-25","volume":"7","author":"R van Laar","year":"2014","unstructured":"van Laar R, et al. Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. BMC Med Genomics. 2014;7:25.","journal-title":"BMC Med Genomics"},{"key":"1987_CR112","doi-asserted-by":"publisher","first-page":"820768","DOI":"10.3389\/fonc.2022.820768","volume":"12","author":"C Cerchione","year":"2022","unstructured":"Cerchione C, et al. Gene expression profiling in multiple myeloma: redefining the paradigm of risk-adapted treatment. Front Oncol. 2022;12:820768.","journal-title":"Front Oncol"},{"issue":"10","key":"1987_CR113","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/diseases13100320","volume":"13","author":"D Leonardos","year":"2025","unstructured":"Leonardos D, et al. Applications of multiparameter flow cytometry in the diagnosis, prognosis, and monitoring of multiple myeloma patients. Diseases. 2025;13(10):320.","journal-title":"Diseases"},{"issue":"1","key":"1987_CR114","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41408-024-01024-8","volume":"14","author":"J-r Li","year":"2024","unstructured":"Li J-r, et al. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer J. 2024;14(1):38.","journal-title":"Blood Cancer J"},{"key":"1987_CR115","doi-asserted-by":"crossref","unstructured":"Xiang Y, et al. Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion? Annals of Hematology; 2025. pp. 1\u201318.","DOI":"10.1007\/s00277-025-06241-0"},{"key":"1987_CR116","volume-title":"Methods for the economic evaluation of health care programmes","author":"G Adamiak","year":"2006","unstructured":"Adamiak G. Methods for the economic evaluation of health care programmes. BMJ Publishing Group Ltd; 2006."},{"issue":"22","key":"1987_CR117","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.3390\/cancers13225606","volume":"13","author":"MR Seefat","year":"2021","unstructured":"Seefat MR, et al. A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma. Cancers. 2021;13(22):5606.","journal-title":"Cancers"},{"issue":"4","key":"1987_CR118","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/14737167.2020.1779064","volume":"21","author":"MM Asrar","year":"2021","unstructured":"Asrar MM, et al. A systematic review of economic evaluations of treatment regimens in multiple myeloma. Expert Rev PharmacoEcon Outcomes Res. 2021;21(4):799\u2013809.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"issue":"1","key":"1987_CR119","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41698-024-00711-w","volume":"8","author":"CE Owens","year":"2024","unstructured":"Owens CE, et al. The economic costs of precision medicine for clinical translational research among children with high-risk cancer. NPJ Precision Oncol. 2024;8(1):224.","journal-title":"NPJ Precision Oncol"},{"issue":"5","key":"1987_CR120","doi-asserted-by":"publisher","first-page":"585","DOI":"10.7326\/M22-0846","volume":"176","author":"GF Guzauskas","year":"2023","unstructured":"Guzauskas GF, et al. Population genomic screening for three common hereditary conditions: a cost-effectiveness analysis. Ann Intern Med. 2023;176(5):585\u201395.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1987_CR121","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/jamia\/ocae089","volume":"31","author":"VL Payne","year":"2024","unstructured":"Payne VL, et al. Clinician perspectives on how situational context and augmented intelligence design features impact perceived usefulness of sepsis prediction scores embedded within a simulated electronic health record. J Am Med Inf Assoc. 2024;31(6):1331\u201340.","journal-title":"J Am Med Inf Assoc"},{"issue":"8","key":"1987_CR122","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/jme-2023-109338","volume":"50","author":"K Kostick-Quenet","year":"2024","unstructured":"Kostick-Quenet K, et al. Trust criteria for artificial intelligence in health: normative and epistemic considerations. J Med Ethics. 2024;50(8):544\u201351.","journal-title":"J Med Ethics"},{"key":"1987_CR123","doi-asserted-by":"publisher","first-page":"e64266","DOI":"10.2196\/64266","volume":"9","author":"S Ackerhans","year":"2025","unstructured":"Ackerhans S, et al. Perceived trust and professional identity threat in AI-based clinical decision support systems: scenario-based experimental study on AI process design features. JMIR Form Res. 2025;9:e64266.","journal-title":"JMIR Form Res"},{"key":"1987_CR124","doi-asserted-by":"publisher","first-page":"106051","DOI":"10.1016\/j.ijmedinf.2025.106051","volume":"204","author":"A Osonuga","year":"2025","unstructured":"Osonuga A, et al. Bridging the digital divide: artificial intelligence as a catalyst for health equity in primary care settings. Int J Med Inf. 2025;204:106051.","journal-title":"Int J Med Inf"},{"key":"1987_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/bmjhci-2024-101124","author":"OJ Canfell","year":"2024","unstructured":"Canfell OJ, et al. Artificial intelligence after the bedside: co-design of AI-based clinical informatics workflows to routinely analyse patient-reported experience measures in hospitals. BMJ Health Care Inform. 2024. https:\/\/doi.org\/10.1136\/bmjhci-2024-101124.","journal-title":"BMJ Health Care Inform"},{"key":"1987_CR126","doi-asserted-by":"publisher","first-page":"110787","DOI":"10.1016\/j.ejrad.2023.110787","volume":"162","author":"K Borys","year":"2023","unstructured":"Borys K, et al. Explainable AI in medical imaging: an overview for clinical practitioners - Saliency-based XAI approaches. Eur J Radiol. 2023;162:110787.","journal-title":"Eur J Radiol"},{"key":"1987_CR127","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41746-018-0040-6","volume":"1","author":"MD Abr\u00e0moff","year":"2018","unstructured":"Abr\u00e0moff MD, et al. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med. 2018;1:39.","journal-title":"NPJ Digit Med"},{"issue":"8","key":"1987_CR128","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/jamainternmed.2021.2626","volume":"181","author":"A Wong","year":"2021","unstructured":"Wong A, et al. External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients. JAMA Intern Med. 2021;181(8):1065\u201370.","journal-title":"JAMA Intern Med"},{"key":"1987_CR129","doi-asserted-by":"publisher","first-page":"105377","DOI":"10.1016\/j.ijmedinf.2024.105377","volume":"184","author":"L Marco-Ruiz","year":"2024","unstructured":"Marco-Ruiz L, et al. A multinational study on artificial intelligence adoption: clinical implementers\u2019 perspectives. Int J Med Inf. 2024;184:105377.","journal-title":"Int J Med Inf"},{"issue":"1","key":"1987_CR130","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12909-024-05078-x","volume":"24","author":"L Jafri","year":"2024","unstructured":"Jafri L, et al. Insights from semi-structured interviews on integrating artificial intelligence in clinical chemistry laboratory practices. BMC Med Educ. 2024;24(1):170.","journal-title":"BMC Med Educ"},{"key":"1987_CR131","doi-asserted-by":"publisher","first-page":"119724","DOI":"10.1016\/j.cca.2024.119724","volume":"559","author":"H Hou","year":"2024","unstructured":"Hou H, Zhang R, Li J. Artificial intelligence in the clinical laboratory. Clin Chim Acta. 2024;559:119724.","journal-title":"Clin Chim Acta"},{"issue":"11","key":"1987_CR132","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/clinchem\/hvab165","volume":"67","author":"DS Herman","year":"2021","unstructured":"Herman DS, et al. Artificial intelligence and mapping a new direction in laboratory medicine: A review. Clin Chem. 2021;67(11):1466\u201382.","journal-title":"Clin Chem"},{"issue":"1","key":"1987_CR133","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/bmb\/ldab016","volume":"139","author":"YYM Aung","year":"2021","unstructured":"Aung YYM, Wong DCS, Ting DSW. The promise of artificial intelligence: a review of the opportunities and challenges of artificial intelligence in healthcare. Br Med Bull. 2021;139(1):4\u201315.","journal-title":"Br Med Bull"},{"issue":"1","key":"1987_CR134","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12282-015-0586-y","volume":"23","author":"Y Tazawa","year":"2016","unstructured":"Tazawa Y. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan. Breast Cancer. 2016;23(1):19\u201323.","journal-title":"Breast Cancer"},{"key":"1987_CR135","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, et al. TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.","journal-title":"BMJ"},{"key":"1987_CR136","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","author":"KG Moons","year":"2025","unstructured":"Moons KG, et al. PROBAST\u2009+\u2009AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ. 2025. https:\/\/doi.org\/10.1136\/bmj-2024-082505.","journal-title":"BMJ"},{"issue":"1","key":"1987_CR137","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M18-1376","volume":"170","author":"RF Wolff","year":"2019","unstructured":"Wolff RF, et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170(1):51\u20138.","journal-title":"Ann Intern Med"},{"key":"1987_CR138","doi-asserted-by":"publisher","first-page":"108535","DOI":"10.1016\/j.compbiolchem.2025.108535","volume":"119","author":"I Zafar","year":"2025","unstructured":"Zafar I, et al. Molecular biology in the exabyte era: taming the data deluge for biological revelation and clinical transformation. Comput Biol Chem. 2025;119:108535.","journal-title":"Comput Biol Chem"},{"issue":"4","key":"1987_CR139","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10928-025-09984-5","volume":"52","author":"IP Androulakis","year":"2025","unstructured":"Androulakis IP, et al. The dawn of a new era: can machine learning and large language models reshape QSP modeling? J Pharmacokinet Pharmacodyn. 2025;52(4):36.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"1987_CR140","doi-asserted-by":"publisher","first-page":"e1013526","DOI":"10.1371\/journal.pcbi.1013526","volume":"21","author":"R Yuan","year":"2025","unstructured":"Yuan R, et al. Harmony-based data integration for distributed single-cell multi-omics data. PLoS Comput Biol. 2025;21(9):e1013526.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"1987_CR141","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-0043-1768733","volume":"32","author":"F Magrabi","year":"2023","unstructured":"Magrabi F, Lyell D, Coiera E. Automation in contemporary clinical information systems: a survey of AI in healthcare settings. Yearb Med Inf. 2023;32(1):115\u201326.","journal-title":"Yearb Med Inf"},{"key":"1987_CR142","first-page":"459","volume":"2024","author":"J Ye","year":"2024","unstructured":"Ye J, et al. The role of artificial intelligence for the application of integrating electronic health records and patient-generated data in clinical decision support. AMIA Jt Summits Transl Sci Proc. 2024;2024:459\u201367.","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"issue":"1","key":"1987_CR143","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/hematology.2021000304","volume":"2021","author":"A Visram","year":"2021","unstructured":"Visram A, Cook J, Warsame R. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. Hematol Am Soc Hematol Educ Program. 2021;2021(1):673\u201381.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"1987_CR144","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, et al. Randomized trial of Lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38(11):1126\u201337.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1987_CR145","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"1987_CR146","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024;14(1):158.","journal-title":"Blood Cancer J"},{"key":"1987_CR147","unstructured":"CARDIOL RA. Validation and Updating of Clinical Prediction Models: Why and How?."},{"issue":"11","key":"1987_CR148","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42(11):1229\u201340.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1987_CR149","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3324\/haematol.2018.200253","volume":"104","author":"E Maffini","year":"2018","unstructured":"Maffini E, et al. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica. 2018;104(2):380.","journal-title":"Haematologica"},{"issue":"1","key":"1987_CR150","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41467-024-55308-5","volume":"16","author":"O Nadeem","year":"2025","unstructured":"Nadeem O, et al. Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial. Nat Commun. 2025;16(1):358.","journal-title":"Nat Commun"},{"key":"1987_CR151","doi-asserted-by":"crossref","unstructured":"Zhang SC, Ballas LK. Radiation for multiple myeloma In the era of novel agents: Indications, Safety, and dose Selection. In Seminars In radiation oncology. Elsevier; 2025.","DOI":"10.1016\/j.semradonc.2024.10.004"},{"key":"1987_CR152","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.2147\/JIR.S499403","volume":"18","author":"S Zhang","year":"2025","unstructured":"Zhang S, et al. The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy. J Inflamm Res. 2025;18:4335\u201357.","journal-title":"J Inflamm Res"},{"issue":"24","key":"1987_CR153","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, et al. International myeloma Society\/International myeloma working group consensus recommendations on the definition of High-Risk multiple myeloma. J Clin Oncol. 2025;43(24):2739\u201351.","journal-title":"J Clin Oncol"},{"key":"1987_CR154","doi-asserted-by":"publisher","first-page":"1458638","DOI":"10.3389\/fimmu.2024.1458638","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, et al. Unveiling the cellular landscape: insights from single-cell RNA sequencing in multiple myeloma. Front Immunol. 2024;15:1458638.","journal-title":"Front Immunol"},{"issue":"1","key":"1987_CR155","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41525-022-00340-x","volume":"8","author":"W Pilcher","year":"2023","unstructured":"Pilcher W, et al. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma. NPJ Genomic Med. 2023;8(1):3.","journal-title":"NPJ Genomic Med"},{"issue":"3","key":"1987_CR156","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s11431-023-2541-x","volume":"67","author":"J Kou","year":"2024","unstructured":"Kou J, et al. Flexible assistance strategy of lower limb rehabilitation exoskeleton based on admittance model. Sci China Technological Sci. 2024;67(3):823\u201334.","journal-title":"Sci China Technological Sci"},{"issue":"1","key":"1987_CR157","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41408-018-0160-x","volume":"9","author":"JS Jang","year":"2019","unstructured":"Jang JS, et al. Molecular signatures of multiple myeloma progression through single cell RNA-Seq. Blood Cancer J. 2019;9(1):2.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1987_CR158","doi-asserted-by":"publisher","first-page":"054002","DOI":"10.1088\/1361-6560\/abe04f","volume":"66","author":"D Nguyen","year":"2021","unstructured":"Nguyen D, et al. A comparison of Monte Carlo dropout and bootstrap aggregation on the performance and uncertainty Estimation in radiation therapy dose prediction with deep learning neural networks. Phys Med Biol. 2021;66(5):054002.","journal-title":"Phys Med Biol"},{"key":"1987_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2025.06.005","author":"Y Fuse","year":"2025","unstructured":"Fuse Y, et al. Artificial intelligence in clinical data analysis: a review of large language models, foundation models, digital twins, and allergy applications. Allergol Int. 2025. https:\/\/doi.org\/10.1016\/j.alit.2025.06.005.","journal-title":"Allergol Int"},{"key":"1987_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14124026","author":"P Hadweh","year":"2025","unstructured":"Hadweh P, et al. Machine learning and artificial intelligence in intensive care medicine: critical recalibrations from rule-based systems to frontier models. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14124026.","journal-title":"J Clin Med"},{"key":"1987_CR161","doi-asserted-by":"publisher","first-page":"107441","DOI":"10.1016\/j.compbiomed.2023.107441","volume":"165","author":"S Seoni","year":"2023","unstructured":"Seoni S, et al. Application of uncertainty quantification to artificial intelligence in healthcare: A review of last decade (2013\u20132023). Comput Biol Med. 2023;165:107441.","journal-title":"Comput Biol Med"},{"issue":"11","key":"1987_CR162","doi-asserted-by":"publisher","first-page":"e70056","DOI":"10.1111\/cts.70056","volume":"17","author":"AV Ponce-Bobadilla","year":"2024","unstructured":"Ponce-Bobadilla AV, et al. Practical guide to SHAP analysis: explaining supervised machine learning model predictions in drug development. Clin Transl Sci. 2024;17(11):e70056.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"1987_CR163","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cvdhj.2023.06.001","volume":"4","author":"C Tarabanis","year":"2023","unstructured":"Tarabanis C, et al. Explainable SHAP-XGBoost models for in-hospital mortality after myocardial infarction. Cardiovasc Digit Health J. 2023;4(4):126\u201332.","journal-title":"Cardiovasc Digit Health J"},{"issue":"1182","key":"1987_CR164","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/postmj\/qgad144","volume":"100","author":"C Hu","year":"2024","unstructured":"Hu C, et al. Explainable artificial intelligence model for mortality risk prediction in the intensive care unit: a derivation and validation study. Postgrad Med J. 2024;100(1182):219\u201327.","journal-title":"Postgrad Med J"},{"issue":"4","key":"1987_CR165","first-page":"e57728","volume":"16","author":"M Elhaddad","year":"2024","unstructured":"Elhaddad M, Hamam S. AI-driven clinical decision support systems: an ongoing pursuit of potential. Cureus. 2024;16(4):e57728.","journal-title":"Cureus"},{"key":"1987_CR166","doi-asserted-by":"crossref","unstructured":"Bagheri M et al. AI-driven decision-making in healthcare information systems: a comprehensive review. 2024.","DOI":"10.20944\/preprints202406.0790.v1"},{"key":"1987_CR167","doi-asserted-by":"publisher","DOI":"10.26483\/ijarcs.v16i3.7262","author":"GS Sargam","year":"2025","unstructured":"Sargam GS. AI-DRIVEN CLINICAL DECISION SUPPORT: ENHANCING CARE QUALITY THROUGH EHR-INTEGRATED INTELLIGENCE. International Journal of Advanced Research in Computer Science. 2025. https:\/\/doi.org\/10.26483\/ijarcs.v16i3.7262.","journal-title":"International Journal of Advanced Research in Computer Science"},{"key":"1987_CR168","doi-asserted-by":"publisher","first-page":"110239","DOI":"10.1016\/j.compbiomed.2025.110239","volume":"192","author":"J Yoo","year":"2025","unstructured":"Yoo J, et al. Review learning: real world validation of privacy preserving continual learning across medical institutions. Comput Biol Med. 2025;192:110239.","journal-title":"Comput Biol Med"},{"issue":"1","key":"1987_CR169","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41746-025-01674-3","volume":"8","author":"JT Rosenthal","year":"2025","unstructured":"Rosenthal JT, Beecy A, Sabuncu MR. Rethinking clinical trials for medical AI with dynamic deployments of adaptive systems. Npj Digit Med. 2025;8(1):252.","journal-title":"Npj Digit Med"},{"issue":"1","key":"1987_CR170","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41746-020-00323-1","volume":"3","author":"N Rieke","year":"2020","unstructured":"Rieke N, et al. The future of digital health with federated learning. NPJ Digit Med. 2020;3(1):119.","journal-title":"NPJ Digit Med"},{"issue":"1","key":"1987_CR171","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1038\/s41467-025-56323-w","volume":"16","author":"R Sklavenitis-Pistofidis","year":"2025","unstructured":"Sklavenitis-Pistofidis R, et al. Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic waldenstrom\u2019s macroglobulinemia. Nat Commun. 2025;16(1):1480.","journal-title":"Nat Commun"},{"issue":"3","key":"1987_CR172","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1158\/0008-5472.CAN-22-2654","volume":"84","author":"YB Hagos","year":"2024","unstructured":"Hagos YB, et al. Deep learning enables Spatial mapping of the mosaic microenvironment of myeloma bone marrow Trephine biopsies. Cancer Res. 2024;84(3):493\u2013508.","journal-title":"Cancer Res"},{"key":"1987_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14242891","author":"ME Yahiaoui","year":"2024","unstructured":"Yahiaoui ME, et al. Federated learning with privacy preserving for multi- institutional three-dimensional brain tumor segmentation. Diagnostics. 2024. https:\/\/doi.org\/10.3390\/diagnostics14242891.","journal-title":"Diagnostics"},{"key":"1987_CR174","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15131708","author":"T Zorlu","year":"2025","unstructured":"Zorlu T, et al. Challenges, difficulties, and delayed diagnosis of multiple myeloma. Diagnostics (Basel). 2025. https:\/\/doi.org\/10.3390\/diagnostics15131708.","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"1987_CR175","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","volume":"57","author":"JB Alberge","year":"2025","unstructured":"Alberge JB, et al. Genomic landscape of multiple myeloma and its precursor conditions. Nat Genet. 2025;57(6):1493\u2013503.","journal-title":"Nat Genet"},{"issue":"1","key":"1987_CR176","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s10238-025-01724-w","volume":"25","author":"A Bayani","year":"2025","unstructured":"Bayani A, et al. Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy. Clin Exp Med. 2025;25(1):186.","journal-title":"Clin Exp Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01987-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:20:02Z","timestamp":1767676802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01987-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":176,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1987"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01987-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"92"}}